Alembic Pharma’s (Alembic) Q1FY23 performance was below our estimates due to sharp fall in US sales, which declined 37.3% QoQ to US$47mn on high base in Q4FY22 owing to inventory restocking, lower offtake during the quarter and continuous price erosion in the base business. India business (ex-covid) grew ~20% YoY.